In the latest market close, Gilead Sciences (GILD) reached $72.41, with a -0.21% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq gained 1.58%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.67% over the past month. This has outpaced the Medical sector's gain of 0.31% and the S&P 500's gain of 0.43% in that time.Analysts and investors al ...

When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry’s winners. However, looking through the Bloomberg Billionaires Index, I don’t see one biotech company in the top 100. They must come later. How are biotech stocks doing in 2024? The Nasdaq Biotechnology Index, a list of 215 biotech and pharmaceutical stocks, is doing okay, up nearly 8% year-to-date, but less than half the Nasdaq 100. The gap gets worse over fiv ...

These three dividend vehicles could provide reliable passive income.Dividend stocks can be dual-threat vehicles, offering investors the best of both worlds. Specifically, these equities can act as reliable passive income generators while simultaneously possessing the potential to increase your net worth through share-price appreciation.If you're interested in buying a handful of dividend stocks as part of a passive income strategy, consider investing $51,000 across these three attractive options: AT&T (T 1. ...

Gilead Sciences (GILD) closed the latest trading day at $71.64, indicating a +1.17% change from the previous session's end. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, added 0.2%.Shares of the HIV and hepatitis C drugmaker have appreciated by 10.18% over the course of the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82%.Analysts and investors alike will be keeping a close eye on the ...

As investors buy from tech giants like Nvidia, many other compelling opportunities exist for those looking for growth. Driven by innovation, revenue growth, and an enviable market position, each of these 3 underappreciated stocks offers investors a unique opportunity for profitability. All of them have shown clear signs of potentially growing by double-digit growth in the next few months.These stocks have been overlooked in an environment of modest gains in anticipation of the upcoming economy. However, loo ...

Key TakeawaysRaymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform."The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women.Lenacapavir and PBC treatment seladelpar could see combined annual sales of $3.7 billion by 2030, according to Raymond James' model. Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “m ...

Biotech giant Gilead Sciences, Inc. (GILD) , a leader in HIV drugs, is having a tough run as recent pipeline setbacks disappointed investors and acquisition-related charges adversely impacted the bottom line. The stock has been under pressure owing to these challenges.While the company’s leading HIV franchise maintains momentum and its efforts to build an oncology franchise to diversify its portfolio are encouraging, the failure of late-stage studies evaluating oncology drug Trodelvy (sacituzumab govitecan) ...

Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform."  According to the the brokerage, GILD -- one of Schaeffer's top 2024 picks -- has support over the next five years from two key drug candidates that could increase revenue growth.Overall, analysts are pessimistic towards toward the security, with 14 of 24 covering firms recommending a "hold," and the stock's average 12-month price target stand ...

Gilead Sciences, Foster City, CA Tomsmith585/iStock Unreleased via Getty ImagesGilead Sciences (NASDAQ:GILD) on Thursday announced positive topline results from an interim analysis of its Phase III PURPOSE 1 trial. The trial which tested the efficacy of twice-yearly lenacapavir versus once daily Truvada and Descovy in approximately 5,300 women at risk of contracting HIV in South Africa and Uganda, found 0 incident cases of HIV infection in the lenacapavir group. In other words, among the 2,124 treated wit ...

Gilead Sciences, Inc. (GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1.PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety and efficacy of twice-yearly, subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) and once-daily oral Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF) in more than 5,300 cisgender women and adolescent girls aged 16-25 years across 25 sites in South Africa and three sites in Uganda.B ...